Offering to Provide Comprehensive Image of Individual Whole Genome
SAN DIEGO--(BUSINESS WIRE)--Jun. 10, 2009--
Illumina, Inc. (NASDAQ:ILMN) today unveiled a service program to provide
high-quality personal genome sequencing for consumers. This is the first
service to offer complete coverage of the human genome sequence for
under $50,000. The Personal Genome Sequencing Service is performed in
Illumina’s recently certified CLIA laboratory utilizing Illumina’s
industry leading Genome Analyzer technology. The offering includes
sequencing of an individual’s DNA to 30 times depth, providing
information on SNP variation and other structural characteristics of the
genome such as insertions, deletions and rearrangements.
“Rapidly decreasing costs have made sequencing a pervasive technology
that can begin to be accessed at the consumer level,” said Jay Flatley,
CEO and president of Illumina. “We are entering a new era in genomic
health, where information from an individual’s genome will begin to
inform lifestyle decisions and ultimately assist with health management.
We believe that in the long-run personal genome sequencing will become a
routine practice and the information generated will enable physicians to
make better healthcare decisions for the consumer. By providing this
service now, Illumina can help catalyze the development of the
infrastructure and physician education that will be necessary as genomic
information becomes medically more meaningful.”
Illumina intends to create a social community for the education and
exchange of information for those who have had their genomes sequenced.
As more information becomes available, participants will be in a
position to mine their personal genome sequence data to understand their
identity in ways which have never been possible.
In addition to the sequencing service, Illumina is establishing a
protocol, infrastructure, and community to enable large-scale adoption
of personal genome sequencing. This includes the creation of a network
of partners to offer a variety of services. Data analysis partners,
physicians and genetic counselors will play an important role in
Illumina’s Personal Genome Sequencing Service. A physician’s network is
being created as physicians will be critical to the service – to discuss
the process with the consumer, order the sequencing service, collect DNA
samples and deliver final sequencing data to the consumer.
Illumina is collaborating with a number of partners, including 23andMe,
deCODE Genetics, Knome and Navigenics, to encourage secondary data
analysis such as calculation of disease risk, ancestry, and information
on traits of interest. Genetic counselors will also play a role in
counseling individuals on the results.
As part of the CLIA certification process, Illumina sequenced Jay
Flatley, CEO and president of Illumina and is currently processing three
other individuals’ genomes. Hermann Hauser, Partner, Amadeus Capital
Partners Ltd, is the second individual to have his genome sequenced
through this service. “I am delighted to be the second person to go
through the process to gain the genomic knowledge that will allow a
detailed assessment of potential health risks. I hope and believe that
this will become a widespread practice as correlations between the
genome and potential illnesses become more precise,” said Hauser. Mr.
Flatley and Mr. Hauser both intend to deposit their complete genome
sequence into the public domain in order to contribute to the collective
understanding of the genome. In doing so, they will double the number of
previously-named completed genomes in the public domain.
Two additional individuals who are being sequenced using Illumina’s
Personal Genome Sequencing service include Henry Louis “Skip” Gates,
Jr., Alphonse Fletcher University Professor at Harvard and his father
Henry Louis Gates, Sr. Skip Gates is the Director of the W.E.B. Du Bois
Institute of African and African American Research, has published 12
books, made nine documentary film series and is the Host and
co-Executive Producer of “Faces of America”.
Illumina’s Personal Genome Sequencing Service will be offered for
$48,000. For more information, visit http://www.everygenome.com.
is the leading developer, manufacturer, and marketer of next-generation
life-science tools and integrated systems for the analysis of genetic
variation and biological function. Using our proprietary technologies,
we provide a comprehensive line of products and services that currently
serve the sequencing, genotyping, and gene expression markets, and we
expect to enter the market for molecular diagnostics. Our customers
include leading genomic research centers, pharmaceutical companies,
academic institutions, clinical research organizations, and
biotechnology companies. Our tools provide researchers around the world
with the performance, throughput, cost effectiveness, and flexibility
necessary to perform the billions of genetic tests needed to extract
valuable medical information from advances in genomics and proteomics.
We believe this information will enable researchers to correlate genetic
variation and biological function, which will enhance drug discovery and
clinical research, allow diseases to be detected earlier, and permit
better choices of drugs for individual patients.
"Safe Harbor" Statement under the Private Securities Litigation Reform
Act of 1995: this release may contain forward-looking statements that
involve risks and uncertainties. Among the important factors that could
cause actual results to differ materially from those in any
forward-looking statements are Illumina's ability (i) to develop and
commercialize further our BeadArray™, VeraCode®, and Solexa®
technologies and to deploy new sequencing, gene expression, and
genotyping products and applications for our technology platforms, (ii)
to manufacture robust instrumentation and reagents technology, together
with other factors detailed in our filings with the Securities and
Exchange Commission including our recent filings on Forms 10-K and 10-Q
or in information disclosed in public conference calls, the date and
time of which are released beforehand. We disclaim any intent or
obligation to update these forward-looking statements beyond the date of
Source: Illumina, Inc.
Peter J. Fromen
Director, Investor Relations
Assoc. Director, Corporate Marketing